Fanghe Li1, Weihong Li2, Xingguang Li3, Feng Li4, Linpeng Zhang5, Bingce Wang6, Guangrui Huang7, Xiaojin Guo8, Liangqin Wan9, Yongqiang Liu10, Sai Zhang11, Soyeon Kang12, Jiabao Ma13. 1. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: fhjingjing@qq.com. 2. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: liweihong.403@163.com. 3. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: lixingguang@hotmail.com. 4. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: lifeng95@vip.sina.com. 5. Department of Clinical Medicine, Weifang Medical University, No 7166 Bao Tong Street, Weifang, Shandong Province 261053, China. Electronic address: zhanglinpeng1608@126.com. 6. Xingzhi Academy, The Affiliated High School of Peking University, No 15 Da Ni Wan Road, Hai Dian District, Beijing 100080, China. Electronic address: wangbingce@stu.pkuschool.edu.cn. 7. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: Huangggr2011@126.com. 8. Department of Pharmacy, Beijing Tongzhou District Hospital of Integrated Chinese Medicine and Western Medicine, No 89 Che Zhan Road, Tong Zhou District, Beijing 101100, China. Electronic address: 597406909@qq.com. 9. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: 779264240@qq.com. 10. Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, No 333 Cottman Avenue, Philadelphia, PA 19111, United States. Electronic address: Yongqiang.liu@fccc.edu. 11. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: 735668409@qq.com. 12. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: 2741510112@qq.com. 13. School of Preclinical Medicine, Beijing University of Chinese Medicine, No 11 Bei San Huan Dong Road, Chao Yang District, Beijing 100029, China. Electronic address: mjbbjm0715@126.com.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Fructus gardenia is widely used for treatment of stroke and infectious diseases in Chinese medicine. Geniposide is the key bioactive compound related to the pharmacodynamic actions of gardenia on ischemic stroke. The molecular mechanism by which geniposide improves the ischemic brain injury was observed in the study. AIM OF THE STUDY: Recent studies showed that geniposide had protective activities against the inflammatory response in ischemic stroke. However, the molecular mechanism of geniposide anti-inflammatory role has not yet been fully elucidated. In this study, we investigated the effect of geniposide on the expression of P2Y14 receptor and downstream signaling pathway in brain microvascular endothelial cells (BMECs). MATERIALS AND METHODS: An in vitro model of cerebral ischemia in BMECs was established by oxygen-glucose-deprivation (OGD). To further confirm the specific effect of geniposide on P2Y14 receptor and downstream signaling pathways, we set up a UDP-glucose (an agonist of the P2Y14 receptor) stimulated model. After administration of geniposide, the expression of P2Y14 receptor, phosphorylation of RAF-1, mitogen activated protein kinase kinase1/2 (MEK1/2), extracellular signal-regulated kinase 1/2 (ERK1/2), level of interleukin-8 (IL-8), interleukin-1β (IL-1β), monocyte chemotactic protein 1 (MCP-1) in BMECs were determined. RESULTS: The mRNA and protein expression of P2Y14 in the rat BMECs were up-regulated in OGD-induced injury. After administration of Geniposide, the expression of P2Y14 receptor was significantly down-regulated, the phosphorylation of RAF-1, MEK1/2, ERK1/2 were suppressed. Similar data were obtained in UDP-glc stimulated model. We also observed that geniposide markedly declined the production of IL-8, IL-1β and MCP-1 in OGD-induced BMECs. CONCLUSION: Geniposide exerted anti-inflammatory effects by interfering with the expression of P2Y14 receptor, which subsequently inhibits the downstream ERK1/2 signaling pathways and the release of the pro-inflammatory cytokines IL-8, MCP-1, IL-1β. Therefore, this study provides the evidence for gardenia's clinical application in cerebral ischemia.
ETHNOPHARMACOLOGICAL RELEVANCE: Fructus gardenia is widely used for treatment of stroke and infectious diseases in Chinese medicine. Geniposide is the key bioactive compound related to the pharmacodynamic actions of gardenia on ischemic stroke. The molecular mechanism by which geniposide improves the ischemic brain injury was observed in the study. AIM OF THE STUDY: Recent studies showed that geniposide had protective activities against the inflammatory response in ischemic stroke. However, the molecular mechanism of geniposide anti-inflammatory role has not yet been fully elucidated. In this study, we investigated the effect of geniposide on the expression of P2Y14 receptor and downstream signaling pathway in brain microvascular endothelial cells (BMECs). MATERIALS AND METHODS: An in vitro model of cerebral ischemia in BMECs was established by oxygen-glucose-deprivation (OGD). To further confirm the specific effect of geniposide on P2Y14 receptor and downstream signaling pathways, we set up a UDP-glucose (an agonist of the P2Y14 receptor) stimulated model. After administration of geniposide, the expression of P2Y14 receptor, phosphorylation of RAF-1, mitogen activated protein kinase kinase1/2 (MEK1/2), extracellular signal-regulated kinase 1/2 (ERK1/2), level of interleukin-8 (IL-8), interleukin-1β (IL-1β), monocyte chemotactic protein 1 (MCP-1) in BMECs were determined. RESULTS: The mRNA and protein expression of P2Y14 in the rat BMECs were up-regulated in OGD-induced injury. After administration of Geniposide, the expression of P2Y14 receptor was significantly down-regulated, the phosphorylation of RAF-1, MEK1/2, ERK1/2 were suppressed. Similar data were obtained in UDP-glc stimulated model. We also observed that geniposide markedly declined the production of IL-8, IL-1β and MCP-1 in OGD-induced BMECs. CONCLUSION:Geniposide exerted anti-inflammatory effects by interfering with the expression of P2Y14 receptor, which subsequently inhibits the downstream ERK1/2 signaling pathways and the release of the pro-inflammatory cytokines IL-8, MCP-1, IL-1β. Therefore, this study provides the evidence for gardenia's clinical application in cerebral ischemia.